These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 32573788)
1. Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis. Baig AM; Khaleeq A; Syeda H J Med Virol; 2020 Nov; 92(11):2792-2803. PubMed ID: 32573788 [TBL] [Abstract][Full Text] [Related]
2. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
3. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM Elife; 2022 Jan; 11():. PubMed ID: 35072628 [TBL] [Abstract][Full Text] [Related]
5. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines. Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD mBio; 2021 May; 12(3):. PubMed ID: 33975938 [TBL] [Abstract][Full Text] [Related]
6. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189 [TBL] [Abstract][Full Text] [Related]
7. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein. Salem R; El-Kholy AA; Waly FR; Ayman D; Sakr A; Hussein M Mol Immunol; 2022 Jan; 141():287-296. PubMed ID: 34915268 [TBL] [Abstract][Full Text] [Related]
8. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Tan TK; Rijal P; Rahikainen R; Keeble AH; Schimanski L; Hussain S; Harvey R; Hayes JWP; Edwards JC; McLean RK; Martini V; Pedrera M; Thakur N; Conceicao C; Dietrich I; Shelton H; Ludi A; Wilsden G; Browning C; Zagrajek AK; Bialy D; Bhat S; Stevenson-Leggett P; Hollinghurst P; Tully M; Moffat K; Chiu C; Waters R; Gray A; Azhar M; Mioulet V; Newman J; Asfor AS; Burman A; Crossley S; Hammond JA; Tchilian E; Charleston B; Bailey D; Tuthill TJ; Graham SP; Duyvesteyn HME; Malinauskas T; Huo J; Tree JA; Buttigieg KR; Owens RJ; Carroll MW; Daniels RS; McCauley JW; Stuart DI; Huang KA; Howarth M; Townsend AR Nat Commun; 2021 Jan; 12(1):542. PubMed ID: 33483491 [TBL] [Abstract][Full Text] [Related]
9. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library. Kim YJ; Lee MH; Lee SR; Chung HY; Kim K; Lee TG; Kim DY Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671877 [TBL] [Abstract][Full Text] [Related]
10. Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2. Lai YC; Cheng YW; Chao CH; Chang YY; Chen CD; Tsai WJ; Wang S; Lin YS; Chang CP; Chuang WJ; Chen LY; Wang YR; Chang SY; Huang W; Wang JR; Tseng CK; Lin CK; Chuang YC; Yeh TM Front Immunol; 2022; 13():868724. PubMed ID: 35603169 [TBL] [Abstract][Full Text] [Related]
11. Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses Vishwakarma P; Yadav N; Rizvi ZA; Khan NA; Chiranjivi AK; Mani S; Bansal M; Dwivedi P; Shrivastava T; Kumar R; Awasthi A; Ahmed S; Samal S Front Immunol; 2021; 12():613045. PubMed ID: 33841395 [TBL] [Abstract][Full Text] [Related]
12. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR Front Immunol; 2021; 12():691715. PubMed ID: 34149735 [TBL] [Abstract][Full Text] [Related]
13. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
14. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270 [TBL] [Abstract][Full Text] [Related]
15. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Yuan M; Liu H; Wu NC; Wilson IA Biochem Biophys Res Commun; 2021 Jan; 538():192-203. PubMed ID: 33069360 [TBL] [Abstract][Full Text] [Related]
16. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Tian X; Li C; Huang A; Xia S; Lu S; Shi Z; Lu L; Jiang S; Yang Z; Wu Y; Ying T Emerg Microbes Infect; 2020; 9(1):382-385. PubMed ID: 32065055 [TBL] [Abstract][Full Text] [Related]
17. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS-CoV-2 neutralization. de Lima VA; Nunes JPS; Rosa DS; Ferreira R; Oliva MLV; Andreata-Santos R; Duarte-Barbosa M; Janini LMR; Maricato JT; Akamatsu MA; Ho PL; Schenkman S Immun Inflamm Dis; 2024 Jul; 12(7):e1353. PubMed ID: 39056544 [TBL] [Abstract][Full Text] [Related]
18. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
19. Establishment of Neutralizing Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 by the Screening with Exosomes Expressing the Viral Spike Protein. Okada C; Ikeda-Ishizaka E; Ono C; Matsuura Y; Sonoda H Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):173-180. PubMed ID: 36027043 [TBL] [Abstract][Full Text] [Related]
20. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]